JP2022501383A5 - - Google Patents
Info
- Publication number
- JP2022501383A5 JP2022501383A5 JP2021515616A JP2021515616A JP2022501383A5 JP 2022501383 A5 JP2022501383 A5 JP 2022501383A5 JP 2021515616 A JP2021515616 A JP 2021515616A JP 2021515616 A JP2021515616 A JP 2021515616A JP 2022501383 A5 JP2022501383 A5 JP 2022501383A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- composition according
- prostate cancer
- contrast agent
- metastatic
- Prior art date
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023204832A JP7748438B2 (ja) | 2018-09-21 | 2023-12-04 | シールド剤およびそれらの使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862734690P | 2018-09-21 | 2018-09-21 | |
| US62/734,690 | 2018-09-21 | ||
| PCT/US2019/051903 WO2020061293A1 (en) | 2018-09-21 | 2019-09-19 | Shielding agents and their use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023204832A Division JP7748438B2 (ja) | 2018-09-21 | 2023-12-04 | シールド剤およびそれらの使用 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022501383A JP2022501383A (ja) | 2022-01-06 |
| JPWO2020061293A5 JPWO2020061293A5 (https=) | 2022-09-29 |
| JP2022501383A5 true JP2022501383A5 (https=) | 2022-09-29 |
| JP7429688B2 JP7429688B2 (ja) | 2024-02-08 |
Family
ID=69887812
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021515616A Active JP7429688B2 (ja) | 2018-09-21 | 2019-09-19 | シールド剤およびそれらの使用 |
| JP2023204832A Active JP7748438B2 (ja) | 2018-09-21 | 2023-12-04 | シールド剤およびそれらの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023204832A Active JP7748438B2 (ja) | 2018-09-21 | 2023-12-04 | シールド剤およびそれらの使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20210323985A1 (https=) |
| EP (1) | EP3853213A4 (https=) |
| JP (2) | JP7429688B2 (https=) |
| CN (1) | CN113166087B (https=) |
| WO (1) | WO2020061293A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112015011118B1 (pt) * | 2012-11-15 | 2022-12-13 | Endocyte, Inc | Conjugado; composição farmacêutica; e uso de um conjugado |
| BR112016010927A2 (pt) | 2013-11-14 | 2017-08-08 | Endocyte Inc | Conjugado de fórmula |
| US12208102B2 (en) | 2018-04-17 | 2025-01-28 | Endocyte, Inc. | Methods of treating cancer |
| CN114096264B (zh) | 2019-05-20 | 2025-03-14 | 因多塞特股份有限公司 | 制备psma缀合物的方法 |
| CA3237590A1 (en) * | 2021-11-09 | 2023-05-08 | James Basilion | Psma targeted conjugate compounds and uses thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2847275T3 (es) * | 2006-11-08 | 2021-08-02 | Molecular Insight Pharm Inc | Heterodímeros de ácido glutámico |
| EP4464384A3 (en) | 2007-08-17 | 2025-01-08 | Purdue Research Foundation | Psma binding ligand-linker conjugates and methods for using |
| WO2012174136A1 (en) * | 2011-06-15 | 2012-12-20 | Cancer Targeted Technology Llc | Chelated psma inhibitors |
| BR112015011118B1 (pt) * | 2012-11-15 | 2022-12-13 | Endocyte, Inc | Conjugado; composição farmacêutica; e uso de um conjugado |
| LT4095130T (lt) * | 2013-10-18 | 2024-04-25 | Novartis Ag | Žymėti prostatos specifinio membranos antigeno (psma) inhibitoriai, jų naudojimas kaip vizualizavimo medžiagų ir farmacinių medžiagų prostatos vėžiui gydyti |
| US9988407B2 (en) | 2014-08-06 | 2018-06-05 | The Johns Hopkins University | Prodrugs of prostate specific membrane antigen (PSMA) inhibitor |
| AU2015315465B2 (en) | 2014-09-08 | 2019-08-29 | Molecular Insight Pharmaceuticals, Inc. | Organ protection in PSMA-targeted radionuclide therapy of prostate cancer |
| SG11201909513QA (en) | 2017-04-11 | 2019-11-28 | Univ Johns Hopkins | Prodrugs of 2-pmpa for healthy tissue protection during psma-targeted cancer imaging or radiotherapy |
-
2019
- 2019-09-19 EP EP19863710.0A patent/EP3853213A4/en active Pending
- 2019-09-19 CN CN201980076992.7A patent/CN113166087B/zh active Active
- 2019-09-19 JP JP2021515616A patent/JP7429688B2/ja active Active
- 2019-09-19 WO PCT/US2019/051903 patent/WO2020061293A1/en not_active Ceased
- 2019-09-19 US US17/277,806 patent/US20210323985A1/en active Pending
-
2023
- 2023-12-04 JP JP2023204832A patent/JP7748438B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022501383A5 (https=) | ||
| Mathias et al. | Synthesis of [99mTc] DTPA-folate and its evaluation as a folate-receptor-targeted radiopharmaceutical | |
| Meredith et al. | Phase II study of interferon-enhanced 131I-labeled high affinity CC49 monoclonal antibody therapy in patients with metastatic prostate cancer | |
| JP7084350B2 (ja) | 放射線療法用粒子と懸濁液 | |
| CN102171187A (zh) | Psma-结合剂及其用途 | |
| JP2021522193A5 (https=) | ||
| JP2020531463A5 (https=) | ||
| Pfestroff et al. | Current status and future perspectives of PSMA-targeted therapy in Europe: opportunity knocks | |
| JP2019527740A5 (https=) | ||
| Shinto et al. | Clinical utility of 188Rhenium-hydroxyethylidene-1, 1-diphosphonate as a bone pain palliative in multiple malignancies | |
| Du et al. | Preliminary evaluation of alpha-emitting radioembolization in animal models of hepatocellular carcinoma | |
| El-Mabhouh et al. | 188Re-labeled bisphosphonates as potential bifunctional agents for therapy in patients with bone metastases | |
| Dormehl et al. | Biodistribution and pharmacokinetics of variously sized molecular radiolabelled polyethyleneiminomethyl phosphonic acid as a selective bone seeker for therapy in the normal primate model | |
| JP2006523664A5 (https=) | ||
| JPWO2020061293A5 (https=) | ||
| Kim et al. | Preclinical evaluation of isostructural Tc-99m-and Re-188-folate-Gly-Gly-Cys-Glu for folate receptor-positive tumor targeting | |
| JP2008533079A5 (https=) | ||
| Riva et al. | Radioimmunotherapy of CMS Malignant Gliomas by Direct Intralesional Injection of Specific 131| Radiolabeled Monoclonal Antibodies | |
| Dallagi et al. | Synthesis and Biodistribution of 1-[2-(cyclopentadienyltricarbonyltechnetium-99m)-2-oxo-ethoxy-phenyl]-1, 2-di-(p-hydroxyphenyl) but-1-ene for tumor imaging | |
| JP7239662B2 (ja) | 複合体、造影剤、及びｃｘｃｒ４関連疾患を治療又は診断するための医薬品 | |
| JP2017514829A5 (https=) | ||
| JP2003512296A (ja) | がんの治療における放射性シスプラチン | |
| Shinto et al. | Important clinical applications of 188Rhenium for radionuclide therapy | |
| Damiana et al. | EANM'23 Abstract Book Congress Sep 9-13, 2023 | |
| CN119874628B (zh) | 一种含氮化合物及其制备方法与用途 |